



International Journal of Preclinical & Pharmaceutical Research

Journal homepage: www.preclinicaljournal.com

ADVANCES IN PROTEOMICS FOR DRUG DISCOVERY AND DEVELOPMENT: FROM ANALYTICAL PLATFORMS TO MULTI-OMICS

Shaik Suhana Tahrannum^{1*}, Diyanka G¹, Ramya Sri V¹, Harshitha V¹, Rajani G²

¹Pharm.D Intern, Department of Pharmacy Practice, KLR Pharmacy College, Paloncha, Telangana, India.

²Associate Professor, Department of Pharmacy Practice, KLR Pharmacy College, Paloncha, Telangana, India.

ABSTRACT

Proteomics has become the backbone of drug discovery and development in the modern world because it allows study of proteins, which are major functional moieties in biological systems to be thoroughly analyzed. In contrast to genomics and transcriptomics, which give indirect data about cellular activity, proteomics directly measures protein expression, structure, interaction, and post-translational modifications that regulate the processes of physiological and pathological activities. The more recent developments in analysing platforms have been in the areas of mass spectrometry-based methods, high-throughput methods, and quantitative proteomic approaches, which have significantly increased the sensitivity, accuracy, and magnitude of protein analysis. These technological advances have increased the speed of drug target identification and validation, discovery of biomarkers and understanding of drug mechanisms of action and toxicity profiles. Moreover, multi-omics integrations of proteomics with genomic and transcriptomic patterns have given a system perspective of disease biology, which is more dependable in choosing targets and tailoring treatment plans. Bioinformatics and computational tools are essential in handling and analyzing large proteomic data-sets so as to enable functional annotation, pathway analysis and network modeling of protein interactions. All these advancements have seen proteomics evolve to be more than a descriptive research tool to a predictive, translational platform in pharmaceutical research. With the ongoing development of innovations like single-cell proteomics, artificial intelligence analysis, and integrative omics, proteomics will keep enhancing the performance of drug discovery pipelines and enable the development of precision medicine. The presented review identifies the major developments in proteomic technologies and their contribution to drug discovery and development and points to the significance of integrating multi-omics in gaining a complete understanding of the disease pathophysiology and the response to drugs.

Key Words: Calcium Proteomics; Drug discovery; Mass spectrometry Multi-omics integration.

INTRODUCTION

Proteomics is currently the fastest growing field of science that has an impact on the contemporary pharmaceutical development and discovery. [1] As the majority of drugs work by interacting with proteins, e.g. enzymes, receptors, ion channels, and transporters, the mechanism of protein expression Structure, activity and regulation is central to the identification of therapeutic targets and the development of effective interventions. Recent developments in proteomics have helped

scientists to leave behind the study of individual proteins as isolated entities, and study complete protein networks that mediate disease pathogenesis, response to treatment, and resistance to drugs. [2] The dynamic and diverse nature of proteome is one of the key reasons why proteomics is essential in the pharmaceutical research. The proteome in contrast to the genome is a relatively stable structure but it varies depending on cell type, developmental stage, environment, and disease condition and drug exposure. Post-translational modifications that include phosphorylation, glycosylation, acetylation, and ubiquitination are also applied to proteins and can radically modify their functions, localization, stability, and interactions.[3] These functional modifications tend to be the reason why the patterns of gene expression are

Corresponding Author

Shaik Suhana Tahrannum

Email: sahmishaik@gmail.com

not necessarily equal to the protein concentration or cellular behavior. Hence, proteomics gives a more immediate and clinically pertinent perspective of biological systems as it catches real-time molecular events that lead to disease pathogenesis and clinical response. The advancement of technology has contributed to the growth of proteomics in drug discovery. [4 -7] On the whole, the development of proteomics, such as the enhancement of analysis platforms and the introduction of comprehensive workflows and multi-omics, has transformed the discovery and development of drugs. Through these advances, researchers can now identify disease-related proteins, confirm therapeutic targets, track drug activity, predict toxicity and comprehend resistance mechanisms more than ever before. With the continued development of proteomic technologies, such as the use of single-cell proteomics and data analysis using artificial intelligence, proteomics is likely to play an even larger role in developing drugs faster and helping patients improve their outcomes by treating them using more specific and personalized therapy.[8]

Techniques in Proteomics

Proteomics is the study of proteins on a wide scale or in large numbers since proteins are the functional molecules that carry out majority of the functions in a cell. Because proteins are highly variable in structure, amount, location and post-translational modifications, special methods of analysis are needed to identify and characterize proteins comprehensively. The current proteomics is based on a set of separation, detection, and data analysis approaches to investigate the complicated protein composition of biological systems.[9 -10] The techniques allow researchers to gain insight into protein expression patterns, protein interactions, and protein functional roles in disease and health, thus offering them useful applications to drug discovery and biomedical research. Although useful, 2D-GE suffers several drawbacks including low resolution of large or small proteins as well as proteins of low abundance, and inability to analyse very hydrophobic membrane proteins. The mass spectrometry (MS) has emerged as the fundamental analysis method in proteomics because it is highly sensitive, accurate and capable of detecting proteins in the lowest concentration. The first thing in a standard proteomic process is to enzymatically digest proteins into peptides which are then ionized by either matrix-assisted laser desorption/ionization (MALDI) or electrospray ionization (ESI). The separated ions are identified according to the mass-to-charge ratio and registered with various categories of mass analysis devices such as time-of-flight (TOF), quadrupole, and orbitrap analyzers. It is possible to ascertain the identity of proteins by comparing the mass spectra that are obtained with that of

protein databases. [11] Post-translational modifications like phosphorylation, glycosylation and acetylation that are important in controlling protein functions can also be studied using MS. Besides the gel and MS based methods, high-throughput proteomic methods have also been designed to examine large number of proteins at once. The LCMS analysis is usually performed to further analyze mixtures of complex peptides that are separated through liquid chromatography (LC). Another technique of importance is protein microarrays, which entails immobilizing thousands of either proteins or antibodies on a solid surface to examine the expression, interactions, or the activities of enzymes in parallel. [12] These are especially effective in screening biomarkers and in large scale protein protein interactions. On the whole, proteomic methods offer great opportunities to investigate dynamic and complicated nature of the proteome. The combination of separation techniques, including 2D-GE with the sophisticated detection systems, like mass spectrometry and high-throughput platforms can provide the researcher with in-depth data regarding protein identity, quantity, and activity.[13] The sensitivity, speed and accuracy of proteomic studies are being improved through continuous advances in instrumentation, sample preparation and data analysis techniques which are becoming essential in the contemporary biological and pharmaceutical research.

Mass Spectrometry (MS)

Mass spectrometry (MS) is among the most crucial methods of analysis in proteomics and is a key method used in the identification, characterization and quantification of proteins. It is grounded into the calculation of mass-to-charge ratio (m/z) of ionized molecules which enables determination of peptide and protein mass accurately. [14] When it comes to proteomic studies, the proteins are most often digested with enzymes like trypsin to reduce size into smaller peptides and then analyzed. Under MALDI, a mixture of the sample and an appropriate matrix is exposed to a laser beam, which induces the desorption and ionization of the analyte. MALDI is commonly combined with time-of-flight (TOF) instruments and can be used to analyze relatively simple peptide mixtures in a short time. Conversely, ESI is a technique in which a high voltage is used on a liquid sample when it flows through a fine capillary to form a spray of charged droplets. ESI commonly is used in liquid chromatography (LC) and it is best suited to complex biological samples. The ions are then separated based on their m/z values with the help of various kinds of mass analyzers after ionization. Some of the common analyzers are a time-of-flight (TOF), quadrupole, ion trap and orbitrap analyzers. The individual analyzers possess certain strengths regarding resolution, sensitivity and mass accuracy. As an example, TOF analyzers are fast analyzed with a broad

mass range, and orbitrap analyzers have high resolution and excellent mass accuracy to conduct a detailed proteomic study. [15,16] Tandem mass spectrometry (MS/MS) is commonly used to gain sequence data of the peptides by further breaking down the peptides of interest and analyzing the resulting peptides. Such pattern of fragmentation is matched with theoretical spectra of the protein databases to determine the matching proteins. Its capacity of protein identification, quantification of level of expression and characterization of structural changes makes it indispensable in biological studies and drug discovery. On-going technological developments in the areas of instrumentation, data processing, and sample preparation are further cutting the boundaries of MS, which is giving an opportunity to explore complex proteomes in greater depth and detail.[17,18]

Two-Dimensional Gel Electrophoresis (2D-GE)

The Two-dimensional gel electrophoresis 2D-GE is a traditional and popular method of proteomics that is used to separate and analyze complex mixtures of proteins..[19] After separation, the proteins are stained with staining methods like Coomassie Brilliant Blue, silver staining or the fluorescent dyes. It has found extensive use in discovering biomarkers, disease profiling and in the study of drug responses. [20,21] Nevertheless, 2D-GE has some flaws despite its benefits. It is less sensitive to low abundance proteins and not as effective with highly hydrophobic membrane proteins as well as very large or small proteins. Furthermore, the method is labor intensive and can vary across runs and this can compromise reproducibility. Altogether, one can conclude that 2D-GE is still a useful method in proteomics, particularly to represent the pattern of protein expression and identify protein variants. Despite the appearance of newer gel-free and high-throughput proteomic techniques, 2D-GE remains a supplementary technique because of allowing a direct visual view of the proteome. The reliability and relevance of gel technology in contemporary proteomic studies are being bolstered by constant advancements in gel technology, staining procedures, and image processing [22,23]

Applications of Proteomics in Drug Discovery

Proteomics has become an important part of the modern drug discovery process as it allows investigating proteins in large quantities, as they are the targets of most therapeutic agents. Compared to genomics, which can give the information on the potential gene expression, proteomics can give first-hand insight on the functional molecules related to the biological processes. The research on the protein levels of expression, structure, interaction, and modifications allows researchers to understand the disease mechanisms and

determine appropriate molecular targets to develop a drug. [24–26] The drugs discovery process has been made very efficient and accurate with these applications. Target identification and validation is one of the significant fields of proteomics in drug discovery. Proteomic methods can be used to compare the protein expression profiles between diseased and healthy cells or tissues resulting in the identification of differentially expressed or unique protein expression in disease conditions. The presence of such proteins can pose a potential target of drug-induced therapies in case they are a central component in the disease pathology. Besides, proteomics is useful in confirming these targets, including their presence, abundance and functional relevance in particular biological pathways. The analysis of protein-protein interactions and signaling pathways also contribute to the choice of the right targets as they show their involvement in the complex cellular networks. Biomarker discovery, regardless of whether protein can be used to mark the presence of a disease, its stage, or therapeutic response, is another crucial use.[27,28] The biological fluids, e.g., blood, urine, or cerebrospinal fluid, can be analyzed by proteomics and allow detecting the disease-specific signature of proteins. The biomarkers are useful in early diagnosis, stratification of the patients, and treatment monitoring in clinical trials. Proteomic profiling will also help in the understanding of resistance mechanisms and it has been especially relevant in the cancer therapy where protein expression or post-translational changes can result in decreased drug sensitivity.[29,36] The identification of these resistance-associated proteins is used to come up with new therapeutic strategies that can prevail or prevent resistance. All in all, proteomics is now an inseparable part of drug discovery as it gives a clear picture on the protein activity and control of disease. It improves rational design of new drugs with its applications in target identification, biomarker discovery, optimization of lead and safety assessment. With the steady development of proteomic technologies of increased sensitivity, accuracy, and throughput, their influence on pharmaceutical research should further increase, and a more effective and personalized therapeutic intervention can be achieved.

Target Identification and Validation

Target identification and validation are essential processes during the initial stages of drug discovery as they dictate the types of molecular elements of a disease process that need to be altered by therapeutic reagents. A drug target is commonly a protein, e.g. an enzyme, receptor, ion channel, or transcription factor that is essential in the treatment of the disease. [37,38] Identification of the target entails finding the proteins, which are much changed under disease conditions relative to disease-related changes. The proteomic

profiling of diseased and normal cells or tissues enables the researcher to identify the proteins that are either overexpressed, under expressed or that are unique in the pathological states. Such differentially expressed proteins can participate in some important biological processes like cell signaling, metabolism, or immune responses and can be used as targets of drugs.[39,40] Proteomic methods can help in this process by tracking the changes in downstream protein levels, or signal transduction subsequent to inhibition or activation of target. Through the examination of global proteomic patterns of protein expression after the target has been manipulated, an investigator can identify unwanted alterations in other unrelated pathways, which can represent the possible side effects.[41, 44] The information is crucial in making optimal choices in terms of targets that offer the highest therapeutic effect and the least adverse effects.

High-throughput Proteomic Approaches

The objective of high-throughput proteomic methods is to analyze the large amounts of proteins in a single experiment and at a fast rate to provide the ability to comprehensively investigate intricate biological systems. Such techniques are needed in contemporary drug discovery and systems biology, where it is important to know global patterns of protein expression, protein-protein interactions and their alterations. Through the integration of superior analytical technologies with automation and computational technologies, high-throughput proteomics enables researchers to analyze large numbers of samples simultaneously and enhances efficiency, reproducibility and minimizes time and cost relative to the older proteomic methods. Mass spectrometry in combination with liquid chromatography (LC-MS) is one of the key elements of high-throughput proteomics. The high sensitivity and resolution of protein mixtures in the complex samples are possible through automated sample preparation and LC-MS workflow. Multiplexing methods, including isobaric labeling methods of tandem mass tags (TMT), isobaric tags of relative and an absolute quantification (iTRAQ), enable multiple samples to be tested during one experiment.[45-47] It assists in the comprehension of the drug candidates mechanism of action and reveals off-target effects in its initial phase. Quantitative proteomics also facilitates dose and response experiments and time course experiments, which is detailed information on the reaction of protein networks to pharmacological treatments. These data-led strategies enhance the process of identifying lead compounds with potential and minimizing the chances of failures in the later stages. In spite of their benefits, proteomic methods with high throughput have issues of complexity of data, instrument sensitivity, and standardization. [48,49] The large

quantities of data, which are generated, necessitate advanced bioinformatics tools in processing, normalization and interpretation. Reproducibility can also be influenced by changes in sample preparation and instrument performance. Thus, to ensure reliable results, it is necessary to design the study in a robust way, implement quality control, and introduce standardized protocols. Combination of high-throughput proteomic data with the knowledge of genomics and transcriptomics further aids in maximizing interpretation of the biological aspects as well as helps in systems-level comprehension of disease processes. Altogether, the high-throughput proteomic methods have revolutionized the study of proteins as they have allowed analyzing them in large scale, quickly, and quantitatively. They have been extremely useful in the research of pharmaceuticals because of their use in biomarker discovery, target identification, and drug screening. High-throughput proteomics will contribute a greater role to precision medicine and the rational development of drugs with further progress in instrumentation, automation and data analysis.[50]

Proteomic Profiling and Screening

Proteomic profiling and screening are potent methods that are applied to examine the global protein expression patterns and determine alterations linked with disease conditions, drug exposure or environmental stimuli. These are intended to produce complete protein expression maps that indicate the functional condition of a cell, tissue, or organism. A comparison of protein profiles of normal and diseased samples enables scientists to determine which proteins are differentially expressed or only expressed under certain conditions. These protein signatures give the understanding of the changes in biological pathways and may suggest the biomarkers or therapeutic targets. Additional innovations in liquid chromatography-mass spectrometry and labeling quantification methods have increased the quality and degree of proteomic profiling and thousands of proteins can be detected in one experiment [51,52]. Proteomic screening can be defined as the mass screening of protein responses to all sorts of stimuli, especially drug candidates or genetic perturbations. The cells or tissues are subjected to various compounds in drug discovery and the pattern of resultant protein expression is examined to determine the effect of the drug on cells. This will aid in the identification of the mechanism of action of candidate drugs as it would provide insight into which signaling pathways or metabolic processes are altered by them. Proteomic screening can also be used to identify off-target effects and changes in proteins that are indicative of toxicity early in drug design to ensure safe drugs. Massive parallel systems and robots allow the high-throughput screening of hundreds of compounds in hundreds of

samples, making the lead compounds screening more efficient. A major advantage of proteomic profiling and screening lies in their capability to identify post-translational modification like phosphorylation, acetylation and ubiquitination. [53,54] These changes tend to control protein activity and signaling and are not represented at the gene expression level. Proteomic methods enable a better understanding of the mechanisms of regulations, as well as disease-specific changes by studying altered proteins.

Quantitative Proteomics for Drug Development

Quantitative proteomics is an advanced field of proteomics that aims at quantifying protein changes during varying biological situations.[1,55] Label-based methods entail the addition of stable isotopes to proteins or peptides in order to allow the samples to be differentiated and compared in a single mass spectrometry run. Popular methods are isotope-coded affinity tag (ICAT), isobaric relative and absolute quantification tags (iTRAQ) and tandem mass tags (TMT). The tools permit multiplexing, which means that a large number of samples can be analyzed at the same time and the accuracy is enhanced by reducing experimental variability. [56] The researcher would be able to know whether the target of interest is being affected by the drug candidate and the downstream pathways which are involved in the response to the drug by comparing the protein expression profiles pre- and post-treatment with the drug candidate. This assists in validating the interest of targets, and gives an indication on the cellular processes that a drug interacts. Dose response and time course studies are also aided by

quantitative proteomics and thus the effects of change in protein concentrations over different drug concentrations and periods can be assessed. Quantitative proteomics could also be applied to safety and toxicity assessment. Changes in certain proteins due to the drug use can be introduced as the initial signs of the organ toxicity or negative reactions. As an illustration, a liver or kidney-related proteins change can indicate possible hepatotoxicity or nephrotoxicity. [57,58] The early identification of such alterations by quantitative proteomics can avert the unsafe compounds, which would otherwise be subjected to expensive clinical trials. It also helps in determining the biomarkers that may be applied to monitor the safety of drugs in the patients at later stages of development. The challenges that are associated with quantitative proteomics even with its benefits include the limitation on identification of small proteins, technical inconsistencies, and the need for multifaceted data analysis procedures. To get credible results, it is necessary to prepare samples of high quality, to have a developed experimental design, and to resort to sophisticated bioinformatics tools. Combination of quantitative proteomic data with genomic and transcriptomic information also increases the interpretation and promotes a systems level perception of drug activity and biology of disease. Its use in target validation, mechanism-of-action studies and toxicity assessment enhances the efficiency and success rate of drug discovery. As the technology advances further, the role of quantitative proteomics in the development of safe, effective and personalized medicines is likely to increase.[59, 60].

Table 1: Key Proteomics Techniques and Their Features


Technique	Key Feature	Advantages	Limitations
2D-Gel Electrophoresis (2D-GE)	Separates proteins by pI and molecular weight	Visual patterning, effective for isoform/PTM analysis	Low sensitivity for low-abundance/membrane proteins
Mass Spectrometry (MS)	Detects peptide mass-to-charge ratios	High sensitivity, accurate quantification, PTM detection	Expensive, complex data analysis
LC-MS/MS	Combines chromatography with tandem MS	High throughput, identifies thousands of proteins	Requires advanced instrumentation
Protein Microarrays	Uses immobilized proteins/antibodies	Parallel analysis, biomarker screening	Limited to available antibodies, lower sensitivity
Label-Based Quantification	Uses tags (TMT/iTRAQ) for sample multiplexing	High accuracy, enables comparison between conditions	Costly, potential labeling bias
Label-Free Quantification	Measures spectral count or ion intensity	Cost-effective, large-scale sample screening	Requires strong normalization; less precise

Table 2: Applications of Proteomics in Drug Discovery

Application	Proteomic Role	Example Output
Target Identification	Identifies differentially expressed/modified proteins	Disease-specific overexpressed kinases
Target Validation	Confirms functional relevance via perturbation studies	Downstream pathway reversal post-inhibitor
Biomarker Discovery	Detects disease/treatment-specific proteins in fluids/tissues	Cancer-specific plasma protein signature
Mechanism-of-Action Studies	Compares pre- vs post-treatment proteomes	Drug-induced signaling pathway alteration
Toxicity Prediction	Identifies protein changes indicating organ toxicity	Liver enzyme profile indicating hepatotoxicity
Lead Compound Screening	High-throughput drug effect profiling	Proteomic shifts post compound exposure

Table 3: Advantages of Multi-Omics Integration in Drug Discovery

Omics Layer	Biological Insight Provided	Combined Value with Proteomics
Genomics	DNA mutations, SNPs, copy number variations	Identifies potential protein-altering mutations
Transcriptomics	RNA expression levels	Suggests transcriptional control of proteins
Proteomics	Protein abundance, structure, PTMs	Captures real-time functional states of the cell
Integrated Insight	Multi-layer regulation of disease pathways	Improves biomarker reliability and drug response prediction



Challenges and Future Trends in Proteomics

Proteomics has become an effective means of gaining insight into the biological systems on the level of proteins but there are a number of challenges which restrict its potential. The complexity of the proteome is one of the main challenges of proteomic analysis. Each cell can potentially express thousands of proteins with large ranges of changes in abundance, structure and post-translational modifications. Proteins of low abundance, usually of vital regulatory interest, are hard to identify on a background of very abundant proteins. It is a broad

dynamic range that renders the identification and quantification of proteins a technically challenging endeavor. Moreover, proteins are very dynamic molecules whose states of expression and modification vary according to the environment, the course of the disease, and treatments of drug, which makes it even harder to analyze it. [61] Data generation and interpretation is another significant problem of proteomics. Mass spectrometry methods are also high-throughput methods resulting in large datasets that need sophisticated bioinformatics software to process and

analyze. Database matching is critical in protein identification and might be restricted by missing protein annotations or sequence differences.[62] Post-translational modifications that are essential in protein functioning can be lost or changed during handling of the sample. Such constraints also influence the quality and the coverage of proteomic profiles and may limit their use in clinical and pharmaceutical studies. Irrespective of these difficulties, the prospects of proteomics in the future are very bright and supported by the rapid changes in technology.[63]

Data Interpretation and Bioinformatics

Bioinformatics and data interpretation are becoming critical parts of proteomic studies since the current proteomic analysis methods produce massive and multifaceted data that cannot be processed by traditional manual processing systems. Mass spectrometry and protein microarrays among other techniques generate enormous amounts of raw data in the form of peptide masses, ion intensities and protein expression levels. The computation is done with complex computation tools and statistical methods in order to transform this raw data into significant information that could be used in biological research. Bioinformatics offers the tools of processing, analyzing and displaying proteomic data helping in the identification of proteins, determining their abundance, and their biological roles.[64,70]

CONCLUSION

Proteomics has already established itself as an innovative pillar in drug development and discovery through offering first-hand information on the proteins that control cellular dysfunction and disease occurrence. Whereas genomics and transcriptomics can provide great

upstream data on the expression of genes and RNAs, proteomics represents the practicality of biological systems such as protein abundance, isoforms, interactions, and post-translational modifications. The fact that the main targets and effectors of most therapeutic agents are proteins has led to a better understanding of disease drivers, molecular mechanisms, and the creation of more effective and clinically relevant interventions due to the possibility to study them in a comprehensive way. It is also becoming more and more apparent that the contribution of proteomics to solving multifactorial diseases and to heterogeneity in patient responses can be even better achieved by the transition to the focus on complex protein networks than on individual proteins. The development of analysis platforms has significantly increased the level and accuracy of proteomic studies. These technologies are useful during important phases of pharmaceutical research, such as the identification and validation of targets, the discovery of biomarkers, the screening of lead compounds, or the safety assessment. Critically, proteomic profiling enables the researcher to visualize changes in pathways following drug exposure to aid in the clarification of mechanism of action, off-target effects, and to identify early signs of toxicity. This evidence-based knowledge limits the uncertainty in candidate selection and it can minimize the possibility of failure of clinical trials at a late stage. High throughput proteomic systems have also further increased the rate of drug discovery because now thousands of samples, disease conditions, and drug candidates can be screened. There has been the support of faster and reproducible analysis in large cohort by automated workflows, enhanced chromatography, and enhanced instrument performance.

REFERENCES

1. Dogiparthi LK, Bukke SPN, Thalluri C, Thalamanchi B, Vidya KP, Sree GN, et al. The role of genomics and proteomics in drug discovery and its application in pharmacy. *Discov. Appl. Sci.*, 7, 2025, Article number not specified.
2. Kerdumthong K, Roytrakul S, Songsurin K, Pratummanee K, Runsaeng P, Obchoei S. Proteomics and Bioinformatics Identify Drug-Resistant-Related Genes with Prognostic Potential in Cholangiocarcinoma. *Biomolecules*, 14(8), 2024, 969.
3. Jia H, Jiang L, Shen X, Ye H, Li X, Zhang L, et al. Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies. *Mol. Cancer*, 24, 2025, Article number not specified.
4. Zhai L-H, Chen K-F, Hao B-B, Tan M-J. Proteomic characterization of post-translational modifications in drug discovery. *Acta Pharmacol. Sin.*, 43, 2022, 3112–3129.
5. Sivanich MK, Gu T-J, Tabang DN, Li L. *et al.* Recent advances in isobaric labeling and applications in quantitative proteomics. *Proteomics*, 22, 2022, 2100256.
6. Yarbro JM, Shrestha HK, Wang Z, Zhang X, Zaman M, Chu M, *et al.* Proteomic landscape of Alzheimer's disease: emerging technologies, advances and insights (2021–2025). *Mol. Neurodegener.*, 20, 2025,
7. Wolde T, Bhardwaj V, Pandey V. Current Bioinformatics Tools in Precision Oncology. *MedComm*, 6, 2025,
8. Zhou Y, Peng S, Wang H, Cai X, Wang Q. *et al.* Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products. *Genes*, 15(4), 2024, 468.
9. Su J, Yang L, Sun Z, Zhan X. *et al.* Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. *Mol. Cell. Proteomics*, 23, 2024, 100737.

10. Li J, Shi A, Liu H, Hu H, Wang Q, Adhikari B, et al. Effect of Hydrothermal Cooking Combined with High-Pressure Homogenization and Enzymatic Hydrolysis on the Solubility and Stability of Peanut Protein at Low pH. *Foods*, 11(9), 2022, 1289.
11. Neagu A-N, Jayathirtha M, Baxter E, Donnelly M, Petre BA, Darie CC. et al. Applications of Tandem Mass Spectrometry (MS/MS) in Protein Analysis for Biomedical Research. *Molecules*, 27(8), 2022, 2411.
12. Yang Y, Qiao L. Data-independent acquisition proteomics methods for analyzing post-translational modifications. *Proteomics*, 23, 2022, 2200046.
13. Guo T, Steen JA, Mann M. et al. Mass-spectrometry-based proteomics: from single cells to clinical applications. *Nature*, 638, 2025, 901–911.
14. Kaskow JA, Hahnert ET, Porter TK, Lu Y, Stanev V, Niu C, et al.. Predicting Peptide Ionization Efficiencies for Electrospray Ionization Mass Spectrometry Using Machine Learning. *J. Am. Soc. Mass Spectrom.*, 35, 2024, 2297–2307.
15. Stewart HI, Grinfeld D, Giannakopoulos A, Petzoldt J, Shanley T, Garland M, et al. Parallelized Acquisition of Orbitrap and Astral Analyzers Enables High-Throughput Quantitative Analysis. *Anal. Chem.*, 95, 2023, 15656–15664.
16. He Y, Shishkova E, Peters-Clarke TM, Brademan DR, Westphall MS, Bergen D, et al.. Evaluation of the Orbitrap Ascend Tribrid Mass Spectrometer for Shotgun Proteomics. *Anal. Chem.*, 95, 2023, 10655–10663.
17. Xie Z, Feng Q, Zhang S, Yan Y, Deng C, Ding C. et al. Advances in proteomics sample preparation and enrichment for phosphorylation and glycosylation analysis. *Proteomics*, 22, 2022, 2200070.
18. Yu K, Wang Z, Wu Z, Tan H, Mishra A, Peng J. et al. High-Throughput Profiling of Proteome and Posttranslational Modifications by 16-Plex TMT Labeling and Mass Spectrometry. *Methods Mol. Biol.*, 2228, 2021, 205–224.
19. Kielkopf CL, Bauer W, Urbatsch IL. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis of Proteins. *Cold Spring Harb. Protoc.*, 2021, 2021,
20. Cao C, Magalhães P, Krapp LF, Bada Juarez JF, Mayer SF, Rukes V, et al. Deep Learning-Assisted Single-Molecule Detection of Protein Post-translational Modifications with a Biological Nanopore. *ACS Nano*, 18, 2023, 1504–1515.
21. Li N, Zhou Y, Wang J, Niu L, Zhang Q, Sun L, et al. Sequential Precipitation and Delipidation Enables Efficient Enrichment of Low-Molecular Weight Proteins and Peptides from Human Plasma. *J. Proteome Res.*, 19, 2020, 3340–3351.
22. Cho K-C, Clark DJ, Schnaubelt M, Teo GC, Leprevost FDV, Bocik W, et al. Deep Proteomics Using Two Dimensional Data Independent Acquisition Mass Spectrometry. *Anal. Chem.*, 92, 2020, 4217–4225.
23. Masood A, Benabdelkamel H, Alfadda AA. Obesity Proteomics: An Update on the Strategies and Tools Employed in the Study of Human Obesity. *High-Throughput*, 7, 2018, 27.
24. Spitz ML, Kashkush A, Benhamou RI. Advancing target validation with PROTAC technology. *Expert Opin. Drug Discov.*, 20, 2025, 551–563.
25. Meissner F, Geddes-McAlister J, Mann M, Bantscheff M. The emerging role of mass spectrometry-based proteomics in drug discovery. *Nat. Rev. Drug Discov.*, 21, 2022, 637–654.
26. Chauhan M, Kumar S, Biswas A, Kumar M, Verma SK, Mishra A, et al. A Comprehensive Review of the Advancement in Omic Technologies in the Field of Drug Discovery and Development. *Lett. Drug Des. Discov.*, 21, 2024, 3319–3331.
27. Azeze GG, Wu L, Alemu BK, Lee WF, Fung LWY, Cheung ECW, et al. Proteomics approach to discovering non-invasive diagnostic biomarkers and understanding the pathogenesis of endometriosis: a systematic review and meta-analysis. *J. Transl. Med.*, 22, 2024,
28. Babaei M, Kashanian S, Lee H, Harding F. et al. Proteomics techniques in protein biomarker discovery. *Quant. Biol.*, 12, 2024, 53–69.
29. Ortega Duran M, Shaheed SU, Sutton CW, Shnyder SD. A Proteomic Investigation to Discover Candidate Proteins Involved in Novel Mechanisms of 5-Fluorouracil Resistance in Colorectal Cancer. *Cells*, 13, 2024, 342.
30. Son A, Park J, Kim W, Yoon Y, Lee S, Ji J, et al. Recent Advances in Omics, Computational Models, and Advanced Screening Methods for Drug Safety and Efficacy. *Toxics*, 12, 2024, 822.
31. Rodrigues JE, Martinho A, Santa C, Madeira N, Coroa M, Santos V, et al. Systematic Review and Meta-Analysis of Mass Spectrometry Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Schizophrenia. *Int. J. Mol. Sci.*, 23, 2022, 4917.
32. Mondello S, Kobeissy FH, Mechref Y, Zhao J, El Hayek S, Zibara K, et al. Searching for Novel Candidate Biomarkers of RLS in Blood by Proteomic Analysis. *Nat. Sci. Sleep*, 13, 2021, 873–883.
33. Rodrigues JE, Martinho A, Santos V, Santa C, Madeira N, Martins MJ, et al. Systematic Review and Meta-Analysis on MS-Based Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Bipolar Disorder. *Int. J. Mol. Sci.*, 23, 2022, 5460.
34. Ayupova AI, Solovyeva VV, Issa SS, Fayoud HJ, Rizvanov AA. et al. Surrogate Biomarkers in Gene Therapy for Orphan Diseases: Validation, Application, and Regulatory Aspects. *Int. J. Mol. Sci.*, 26, 2025, 10107.
35. Liu Y, Gao F, Cheng Y, Qi L, Yu H. et al. Applications and advances of multi-omics technologies in gastrointestinal tumors. *Front. Med.*, 12, 2025, Article number not specified.

36. Dong Y, Song X, Wang X, Wang S, He Z. *et al.* The early diagnosis of Alzheimer's disease: Blood-based panel biomarker discovery by proteomics and metabolomics. *CNS Neurosci. Ther.*, 30, 2024, Article number not specified.
37. Zhang S, Liu K, Liu Y, Hu X, Gu X. *et al.* The role and application of bioinformatics techniques and tools in drug discovery. *Front. Pharmacol.*, 16, 2025, Article number not specified.
38. Das U. Transforming Precision Medicine through Generative AI: Advanced Architectures and Tailored Therapeutic Design for Patient-Specific Drug Discovery. *ChemistrySelect*, 10, 2025, Article number not specified.
39. Wu G, Fan X, Cheng L, Chen Z, Yi Y, Liang J, *et al.* Metabolism-driven posttranslational modifications and immune regulation: Emerging targets for immunotherapy. *Sci. Adv.*, 11, 2025, Article number not specified.
40. Schwarzer E, Skorokhod O. Post-Translational Modifications of Proteins of Malaria Parasites during the Life Cycle. *Int. J. Mol. Sci.*, 25, 2024, 6145.
41. Crawford LJ, Campbell DC, Morgan JJ, Lawson MA, Down JM, Chauhan D, *et al.* The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. *Oncogene*, 39, 2020, 5001–5014.
42. Anguraj Vadivel AK, Pajovic S, Siddaway R, Zhu S, Sbergio S-G, Matic O, *et al.* The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases. *Neuro Oncol.*, 27, 2025, 1829–1846.
43. Wang J, Song X, Wei M, Qin L, Zhu Q, Wang S, *et al.* PCAS: An Integrated Tool for Multi-Dimensional Cancer Research Utilizing Clinical Proteomic Tumor Analysis Consortium Data. *Int. J. Mol. Sci.*, 25, 2024, 6690.
44. Du P, Fan R, Zhang N, Wu C, Zhang Y. *et al.* Advances in Integrated Multi-omics Analysis for Drug-Target Identification. *Biomolecules*, 14, 2024, 692.
45. Burns AP, Zhang Y-Q, Xu T, Wei Z, Yao Q, Fang Y, *et al.* A Universal and High-Throughput Proteomics Sample Preparation Platform. *Anal. Chem.*, 93, 2021, 8423–8431.
46. Schär S, Räss L, Malinowska L, Savickas S, Cavallo F, Below C, *et al.* A Flexible End-to-End Automated Sample Preparation Workflow Enables Standardized and Scalable Bottom-up Proteomics. *Anal. Chem.*, 97, 2025, 22116–22131.
47. Syu G-D, Dunn J, Zhu H. Developments and Applications of Functional Protein Microarrays. *Mol. Cell. Proteomics*, 19, 2020, 916–927.
48. Peters-Clarke TM, Liang Y, Mertz KL, Lee KW, Westphall MS, Hinkle JD, *et al.* Boosting the Sensitivity of Quantitative Single-Cell Proteomics with Infrared-Tandem Mass Tags. *J. Proteome Res.*, 24, 2024, 1539–1548.
49. Saei AA, Sun L, Mahmoudi M. The role of protein corona in advancing plasma proteomics. *Proteomics*, 25, 2024,
50. Singh S, Kumar R, Payra S, Singh SK. Artificial Intelligence and Machine Learning in Pharmacological Research: *Bridging the Gap Between Data and Drug Discovery*. *Cureus*, 15, 2023,
51. Panicucci C, Sahin E, Bartolucci M, Casalini S, Brolatti N, Pedemonte M, *et al.* Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy. *Cell. Mol. Life Sci.*, 81, 2024, specified.
52. Jiang Y, Meyer JG. Rapid Plasma Proteome Profiling via Nanoparticle Protein Corona and Direct Infusion Mass Spectrometry. *J. Proteome Res.*, 23, 2024, 3649–3658.
53. Patwardhan A, Cheng N, Trejo J. Post-Translational Modifications of G Protein-Coupled Receptors Control Cellular Signaling Dynamics in Space and Time. *Pharmacol. Rev.*, 73, 2020, 120–151.
54. Song Y, Ren X, Xiong J, Wang W, Zhao Q, Chang J, *et al.* Ubiquitin-Specific Protease 7 (USP7) as a Promising Therapeutic Target for Drug Discovery: From Mechanisms to Therapies. *J. Med. Chem.*, 68, 2025, 7914–7931.
55. Pan S, Yin L, Liu J, Tong J, Wang Z, Zhao J, *et al.* Metabolomics-driven approaches for identifying therapeutic targets in drug discovery. *MedComm*, 5, 2024,
56. Millán-Oropeza A, Blein-Nicolas M, Monnet V, Zivy M, Henry C. *et al.* Comparison of Different Label-Free Techniques for the Semi-Absolute Quantification of Protein Abundance. *Proteomes*, 10, 2022, 2.
57. Eckert S, Berner N, Kramer K, Schneider A, Müller J, Lechner S, *et al.* Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomics. *Nat. Biotechnol.*, 43, 2024, 406–415.
58. Su R, Yang H, Wei L, Chen S, Zou Q. *et al.* A multi-label learning model for predicting drug-induced pathology in multi-organ based on toxicogenomics data. *PLoS Comput. Biol.*, 18, 2022, e1010402.
59. Kiriiri GK, Njogu PM, Mwangi AN. *et al.* Exploring different approaches to improve the success of drug discovery and development projects: a review. *Future J. Pharm. Sci.*, 6, 2020,
60. Ikwelle TA, Ihim AC, Ozuruoke DFN, Obi PC, Obi CU, Onuora IJ, *et al.* Multi-Omics Integration in Personalized Medicine: Advancing Laboratory Diagnostics and Precision Therapeutics in the Era of Individualized Healthcare. *J. Drug Deliv. Ther.*, 15, 2025, 132–142.
61. Jiang Y, Rex DAB, Schuster D, Neely BA, Rosano GL, Volkmar N, *et al.* Comprehensive Overview of Bottom-Up Proteomics Using Mass Spectrometry. *ACS Meas. Sci. Au*, 4, 2024, 338–417.
62. Ye Z, Sabatier P, Van Der Hoeven L, Phlairaharn T, Hartlmayr D, Izaguirre F, *et al.* High-throughput and scalable single cell proteomics identifies over 5000 proteins per cell. *bioRxiv*, 2023,

63. Petrova B, Guler AT. Recent Developments in Single-Cell Metabolomics by Mass Spectrometry—A Perspective. *J. Proteome Res.*, 24, 2024, 1493–1518.
64. Chen C, Hou J, Tanner JJ, Cheng J. *et al.* Bioinformatics Methods for Mass Spectrometry-Based Proteomics Data Analysis. *Int. J. Mol. Sci.*, 21, 2020, 2873.
65. Somda D, Wilson Kpordze S, Jerpkorir M, Chantelle Mahora M, Wanjiru Ndungu J, Wambui Kamau S, *et al.* The Role of Bioinformatics in Drug Discovery: A Comprehensive Overview. *IntechOpen*, 2024,
66. Kratka K, Sistik P, Olivkova I, Kusnierova P, Svagera Z, Stejskal D. Mass Spectrometry-Based Proteomics in Clinical Diagnosis of Amyloidosis and Multiple Myeloma: A Review (2012–2024). *J. Mass Spectrom.*, 60, 2025,
67. Zhu Y, Orre LM, Zhou Tran Y, Mermelekas G, Johansson HJ, Malyutina A, *et al.* DEqMS: A Method for Accurate Variance Estimation in Differential Protein Expression Analysis. *Mol. Cell. Proteomics*, 19, 2020, 1047–1057.
68. Pammi M, Aghaeepour N, Neu J. Multiomics, artificial intelligence, and precision medicine in perinatology. *Pediatr. Res.*, 93, 2022, 308–315.
69. Hsu C-Y, Askar S, Alshkarchy SS, Nayak PP, Attabi KAL, Khan MA, *et al.* AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. *Clin. Exp. Med.*, 26, 2025,
70. Zhang N, Tang L, Li S, Liu L, Gao M, Wang S, *et al.* Integration of multi-omics data accelerates molecular analysis of common wheat traits. *Nat. Commun.* 16, 2025